In the BioHarmony Drug Report Database
Reslizumab
Cinqair, Cinqaero (reslizumab) is an antibody pharmaceutical. Reslizumab was first approved as Cinqair on 2016-03-23. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. The pharmaceutical is active against interleukin-5.
Trade Name
|
Cinqaero |
|---|---|
Common Name
|
reslizumab |
ChEMBL ID
|
CHEMBL2107884 |
Indication
|
asthma |
Drug Class
|
Monoclonal antibodies: humanized, immunomodulating |
Image (chem structure or protein)
